# Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer

> **NCT03780075** · PHASE1 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** 1.11GBq of 177Lu-EB-PSMA-617
- **DRUG:** 2.00 GBq of 177Lu-EB-PSMA-617
- **DRUG:** 3.70GBq of 177Lu-EB-PSMA-617

## Key facts

- **NCT ID:** NCT03780075
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-15
- **Primary completion:** 2020-09-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-05-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03780075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03780075, "Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03780075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*